An expert shares his insights on the challenges and practical considerations that come with bispecific antibody treatment. Currently, there is no standardization of melphalan administration. A real-world study presented at the EHA 2024 Congress provided insights on patient and caregiver experiences. The risk of hospitalization was associated with the number of drugs in a patient's myeloma treatment regimen. With 3 FDA-approved BiTEs for myeloma, oncology nurses must be able to understand BiTEs and explain them to patients. Talquetamab is a T-cell redirecting bispecific antibody targeting GPRC5D on myeloma cells. Due to the unique challenges associated with administering these therapies, a team aimed to standardize the workflow. Misinformation or fake news can mislead patients with multiple myeloma. Nurse researchers noted patients had “feelings of confusion at the time of initial diagnosis" of multiple myeloma. The study showed that nursing support was a “key environmental facilitator" for physical activity in these patients. Although CRAB describes end-organ symptoms of multiple myeloma, it does not provide a full picture. Myeloma is a complex blood cancer that can be difficult to comprehend, especially the 2 earlier precursor disease stages. Researchers analyzed data from more than 1 million people to determine blood cancer mortality rates from 2000-2020. Age is an important prognostic factor for patients with multiple myeloma. Learn how to ask informed questions, connect patients with resources, and support shared-decision making. Alicia Michaelsen, BSN, RN, BMTCN, discusses the importance of raising awareness. The withdrawal comes 2 years after the FDA granted accelerated approval to the treatment. Oncology nurses must be able to quickly identify hypercalcemia because it can cause cardiac arrest or coma. Hypercalcemia is the most common oncologic emergency, which makes it critical to understand this electrolyte imbalance. A new study shows why it's critical to assess patients for financial and time toxicity.